Real world outcomes in patients with recurrent, advanced, or metastatic endometrial cancer treated with lenvatinib plus pembrolizumab by A. Pawsey, P. Mahalingam, N. Senthivel, A. Ramessur, E. Turnbull, S. Usman, R. Browne, A. Patel, A. Stewart, L. Tookman, N. Counsell, R. Miller, S. Nicum, G. Eminowicz

Subjects: Get full text

A randomized study to evaluate the safety and efficacy of two dosages of lenvatinib – 18 and 24 mg – in patients with radioiodrefract differentiated thyroid cancer by M. S. Brose, Yu. Panaseykin, B. Konda, C. de la Fouchardiere, B. G.M. Hughes, A. G. Gianoukakis, Y. J. Park, I. Romanov, M. K. Krzyzanowska, S. Leboulleux, T. A. Binder, C. Dutcus, R. Xie, M. H. Taylor

Subjects: “…ленватиниб…”
Get full text